Tolerability and efficacy of combination therapy with simvastatin plus gemfibrozil in type IIb refractory familial combined hyperlipidemia
- 1 May 1993
- journal article
- Published by Elsevier in Current Therapeutic Research
- Vol. 53 (5) , 473-483
- https://doi.org/10.1016/s0011-393x(05)80655-1
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Primary and secondary prevention of coronary artery diseaseCurrent Opinion in Cardiology, 1992
- From familial combined hyperlipidemia to hyperapoB: unravelling the overproduction of hepatic apolipoprotein BCurrent Opinion in Lipidology, 1992
- Cholesterol lowering as a treatment for established coronary heart disease.Circulation, 1992
- Long-term safety and efficacy profile of simvastatinThe American Journal of Cardiology, 1991
- Lipid-lowering therapy after an atherosclerotic eventThe American Journal of Cardiology, 1990
- Lipid lowering drugs.BMJ, 1990
- Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.Circulation, 1989
- New Horizons in Combination Drug Therapy for HypercholesterolemiaCardiology, 1989
- Effect of fibric acid derivatives on blood lipid and lipoprotein levelsThe American Journal of Medicine, 1987
- Hyperlipidemia in Coronary Heart Disease II. GENETIC ANALYSIS OF LIPID LEVELS IN 176 FAMILIES AND DELINEATION OF A NEW INHERITED DISORDER, COMBINED HYPERLIPIDEMIAJournal of Clinical Investigation, 1973